breast cancer anti-estrogen resistance 4Genealiases: []
Q-omics provides the consensus-scored BCAR4 profile across patient tissues and cancer cell-line models. BCAR4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, BCAR4 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, BCAR4 RNA expression shows 5,758 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight BRCA, and KIRC as cancer lineages where BCAR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCAR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCAR4 survival associations across molecular data types. BCAR4 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCAR4 RNA expression–survival associations across cancer types. High BCAR4 expression shows unfavorable associations in BRCA, HNSC, LIHC, KIRC and COAD, but favorable associations in READ. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for BCAR4 RNA expression.
This table summarizes BCAR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BCAR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCAR4 shows lower tumor expression in PAAD and higher tumor expression in KIRC, HNSC, BRCA and LUAD. The KIRC box plot shows higher BCAR4 RNA expression in tumor versus normal tissue (log2 FC = +0.021, t-test p < 0.001).
This table shows molecular features associated with BCAR4 in patient tissues and cancer cell lines. In patient samples, BCAR4 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
